Evidence map›Paper›PMID 36839829›Full record

ArticlePharmaceutics2023

Hybrid Manufacturing of Oral Solid Dosage Forms via Overprinting of Injection-Molded Tablet Substrates.

Han Xu, Farnoosh Ebrahimi, Ke Gong, Zhi Cao, Evert Fuenmayor, Ian Major

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 16 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Han XuPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.ORCID 0000-0002-4147-9965
Farnoosh EbrahimiPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.ORCID 0000-0002-2331-4876
Ke GongPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.ORCID 0000-0003-1144-8292
Zhi CaoPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.
Evert FuenmayorPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.ORCID 0000-0001-8982-7845
Ian MajorPRISM Research Institute, Athlone Campus, Technological University of Shannon: Midland and Midwest, N37 HD68 Athlone, Ireland.ORCID 0000-0002-0538-9786
Athlone Institute of Technology · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 3D printing allows for patient-specific dosage forms, it has become a major focus in pharmaceutical research. However, it is difficult to scale up drug product manufacturing. Injection molding has been used in conjunction with hot-melt extrusion to mass produce drug products, but making tailored solid dosage forms with this technology is neither cost-effective nor simple. This study explored the use of a combination of fused filament fabrication and injection molding to create patient-specific solid dosage forms. A tablet fixation and location template was used to overprint directly on injection-molded tablet bases, and theophylline was combined with polycaprolactone and Kollidon

Indexed as

3D printinginjection moldingoverprintingprecision medicinesolid dosage forms

Identifiers

PMID36839829
PMCPMC9965482
OpenAlexW4319158438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.